RxDoctor Payments Data

Harold Miller, MD

Endocrinology, Diabetes & Metabolism · Hammond, LANPI 1295707669

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Abbott at 36.8% of the total. Reporting peaked in 2022 at $18,329 and has fallen 62.8% since, to $6,824 in 2025. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,907in general payments, 2019–2025

Across 1,588 payments — averaging $45.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$27K
  • Merck$10K
  • Mannkind Corporation$5K
  • Medtronic$4K
  • Corcept Therapeutics$2K
  • Eli Lilly$2K
  • plus $22K from 54 others
$1,078,977in research payments, 2019–2025

Across 251 payments — averaging $4298.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$257K
  • Novartis$200K
  • Corcept Therapeutics$152K
  • Bayer$114K
  • AbbVie$111K
  • Genentech, Inc.$84K
  • plus $162K from 3 others

What the payments were for

  • Consulting fees$3,0134%
  • Speaking & faculty fees$26,96837%
  • Travel & lodging$11,05015%
  • Food & beverage$31,71143%
  • Education$1070%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott138$26,794
Merck74$9,991
Mannkind Corporation49$4,948
Medtronic(2 entities)124$4,388
Corcept Therapeutics73$2,332
Eli Lilly28$2,268
Insulet Corporation25$2,196
Lilly USA, LLC121$2,143
Novo Nordisk100$1,616
Amgen(2 entities)65$1,535
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC111$1,494
Xeris Pharmaceuticals, Inc.89$1,378
Dexcom, Inc.69$1,336
Bayer59$1,324
AbbVie69$1,055
AstraZeneca(2 entities)47$991
Sanofi-aventis U.S. LLC66$978
Novartis13$597
Recordati_rare_diseases_inc.20$548
BETA Bionics, Inc.17$407
Amneal Pharmaceuticals LLC27$392
Antares Pharma, Inc.14$311
Boehringer Ingelheim18$299
Amarin Pharma, Inc.15$268
Zealand Pharma US, Inc.9$259
Lifescan, Inc.13$238
Ascendis Pharma Endocrinology Inc7$218
Radius Health, Inc.10$217
Senseonics, Incorporated4$186
BD8$175
Johnson & Johnson12$146
Valeritas, Inc.4$145
Currax Pharmaceuticals LLC9$139
IBSA Pharma Inc.7$119
Ascensia Diabetes Care US Inc.5$104
Cequr Corporation2$103
Embecta Corp.5$95
Nevro Corp.5$83
Madrigal Pharmaceuticals3$82
Alfasigma USA, Inc.5$77
Almatica Pharma LLC3$75
Esperion Therapeutics, Inc.4$72
Neurocrine Biosciences, Inc.3$66
Sequel Med Tech, LLC4$64
Idorsia Pharmaceuticals US Inc4$62
Shire North American Group Inc3$55
Halozyme Inc3$54
Clarus Therapeutics Inc.3$54
Acerus Pharmaceuticals Corporation3$52
Tolmar, Inc.2$44
Ultragenyx Pharmaceutical Inc.2$39
GRT US Holding, Inc.2$38
Regeneron Healthcare Solutions, Inc.1$34
Intra-sana Laboratories1$29
Tandem Diabetes Care, Inc.1$27
Rhythm Pharmaceuticals, Inc.1$25
Eisai Inc.1$19
Pfizer1$17
Evoke Pharma, Inc.1$17
Averitas Pharma Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,907 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana

Medicare billing

Part B allowed, 2024
$126,435
Medicare patients
536
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone69$2,939,911
MounjaroTirzepatide467$622,882
OzempicSemaglutide364$429,276
JardianceEmpagliflozin319$245,174
TrulicityDulaglutide141$163,982
JanuviaSitagliptin Phosphate136$126,413
AfrezzaInsulin Regular, Human62$115,986
TradjentaLinagliptin151$111,685
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog139$94,050
Tresiba Flextouch U-200Insulin Degludec101$92,102
Tresiba Flextouch U-100Insulin Degludec128$78,465
FarxigaDapagliflozin Propanediol94$71,813
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog67$69,277
RybelsusSemaglutide60$68,487
Repatha SureclickEvolocumab68$67,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$2,332$2,939,91169 claims
Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog$2,143$865,243723 claims
Novo NordiskOzempic, Rybelsus, Novolog, Fiasp$1,616$614,381766 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$299$371,522490 claims
MerckJanuvia, Janumet Xr$9,991$145,316155 claims
Mannkind CorporationAfrezza$4,948$115,98662 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$978$73,841134 claims
AstraZenecaFarxiga$991$71,81394 claims
Radius Health, Inc.Tymlos$217$49,12518 claims
AmgenProlia$1,535$43,93925 claims
AbbVieSynthroid$1,055$27,946401 claims
BayerKerendia$1,324$14,52517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

Other endocrinology, diabetes & metabolism in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →